Efficacy of Edaravone and Dexborneol in the Early Treatment of Acute Cerebral Infarction and Its Effect on Cerebrovascular Reserve Capacity,Limb Function and Nerve Injury Factors
Objective:To investigate the effect of edaravone and dexborneol in early treatment of acute cerebral infarction(ACI)and its effect on cerebrovascular reserve capacity,limb function and nerve injury factors.Methods:A total of 100 ACI patients treated in a hospital from April 2020 to October 2021 were selected and divided into observation group and control group by random number table,with 50 patients in each group.The observation group was given edaravone and dexborneol concentrated solution for injection immediately after infusion of alteplase for injection,and the control group was given edaravone and dexborneol concentrated solution for injection 24 hours after the infusion of alteplase for injection.The cerebrovascular reserve capacity[cerebrovascular reserve(CVR),middle cerebral artery pulsatility index(PI)and blood flow rate(BFR)],limb function(sensory function,balance ability,ability to perform activities actively,motor change ability,joint range of motion),nerve injury factors[peroxiredoxin 1(PRDX1),omentin-1,chitinase-like protein-40(YKL-40)],clinical effect and adverse reactions were compared between the two groups.Results:After treatment,PI in the observation group were lower and CVR and BFR were higher than those in the control group(P<0.05).Scores of sensory function,balance ability,ability to perform activities actively,motor change ability and joint range of motion in observation group were higher than those in control group(P<0.05);the levels of PRDX1 and YKL-40 were lower and the level of omentin-1 was higher in the observation group than those in the control group(P<0.05).The total effective rate in observation group was higher than that in the control group(P<0.05).The No statistically significant difference in the total incidence of adverse reactions was observed between the two groups(P>0.05).Conclusion:Edaravone and dxborneol for early treatment of ACI can effectively protect the cerebrovascular reserve capacity,enhance limb function,improve levels of serum nerve injury factors,and prompt the efficacy,and does not increase risks of adverse reactions.
万方数据
维普
